Correlation Between Aridis Pharmaceuticals and Virax Biolabs

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Aridis Pharmaceuticals and Virax Biolabs at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aridis Pharmaceuticals and Virax Biolabs into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Aridis Pharmaceuticals and Virax Biolabs Group, you can compare the effects of market volatilities on Aridis Pharmaceuticals and Virax Biolabs and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aridis Pharmaceuticals with a short position of Virax Biolabs. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aridis Pharmaceuticals and Virax Biolabs.

Diversification Opportunities for Aridis Pharmaceuticals and Virax Biolabs

-0.18
  Correlation Coefficient

Good diversification

The 3 months correlation between Aridis and Virax is -0.18. Overlapping area represents the amount of risk that can be diversified away by holding Aridis Pharmaceuticals and Virax Biolabs Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Virax Biolabs Group and Aridis Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aridis Pharmaceuticals are associated (or correlated) with Virax Biolabs. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Virax Biolabs Group has no effect on the direction of Aridis Pharmaceuticals i.e., Aridis Pharmaceuticals and Virax Biolabs go up and down completely randomly.

Pair Corralation between Aridis Pharmaceuticals and Virax Biolabs

Given the investment horizon of 90 days Aridis Pharmaceuticals is expected to under-perform the Virax Biolabs. In addition to that, Aridis Pharmaceuticals is 1.11 times more volatile than Virax Biolabs Group. It trades about -0.02 of its total potential returns per unit of risk. Virax Biolabs Group is currently generating about 0.01 per unit of volatility. If you would invest  1,090  in Virax Biolabs Group on September 3, 2024 and sell it today you would lose (893.00) from holding Virax Biolabs Group or give up 81.93% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy30.3%
ValuesDaily Returns

Aridis Pharmaceuticals  vs.  Virax Biolabs Group

 Performance 
       Timeline  
Aridis Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Aridis Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental indicators, Aridis Pharmaceuticals is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.
Virax Biolabs Group 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Virax Biolabs Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Aridis Pharmaceuticals and Virax Biolabs Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Aridis Pharmaceuticals and Virax Biolabs

The main advantage of trading using opposite Aridis Pharmaceuticals and Virax Biolabs positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aridis Pharmaceuticals position performs unexpectedly, Virax Biolabs can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Virax Biolabs will offset losses from the drop in Virax Biolabs' long position.
The idea behind Aridis Pharmaceuticals and Virax Biolabs Group pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Other Complementary Tools

Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators